Stockscreener 앱 받기
80.50
7.35%
5.51
시간 외 거래:
80.30
-0.20
-0.25%
Veradermics Inc 주식(MANE)의 최신 뉴스
MANE Stock Price and Chart — NYSE:MANE - TradingView — Track All Markets
Veradermics (MANE) Reports Q4 Net Loss of $21.8M - Yahoo Finance
ETFs Investing in Veradermics, Incorporated Stocks - TradingView — Track All Markets
Number of employees of Veradermics, Incorporated – NYSE:MANE - TradingView — Track All Markets
MANE Forecast — Price Target — Prediction for 2027 - TradingView — Track All Markets
Veradermics, Incorporated Statistics – BX:MANE - TradingView — Track All Markets
Biopharma IPOs Had Their Best Showing In More Than A Year In Q1 - Citeline News & Insights
AMD, Avago among market cap stock movers on Friday - Investing.com
AMD, Avago among market cap stock movers on Friday By Investing.com - Investing.com India
Veradermics, Incorporated: Fundamental Analysis and Financial Ratings | MANE | US9229671048 - marketscreener.com
VeraDermics Surges 9%—Yet Major Investors Remain Cautious - Bitget
MANE SEC FilingsVERADERMICS INC 10-K, 10-Q, 8-K Forms - Stock Titan
MANE: Veradermics IncorporatedBrokerage Recommendations Chart - Zacks Investment Research
Veradermics Shares More Than Double in NYSE Debut - MarketScreener
Citi Maintains Veradermics(MANE.US) With Buy Rating, Maintains Target Price $85 - Moomoo
VeraDermics (MANE) Plummets 7% as Intraday Volatility Unfolds — What's Fueling the Sharp Drop? - Bitget
Veradermics (NYSE: MANE) bets on oral minoxidil for pattern hair loss - Stock Titan
Veradermics, Incorporated Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - marketscreener.com
Veradermics Reports Strong 2025 Financials, Completes Key VDPHL01 Trials, and Raises $295M IPO to Fund Operations Into 2029 - Minichart
Veradermics (NYSE: MANE) deepens 2025 loss after $294.8M IPO cash boost - Stock Titan
MANE: Raised $294.8M in IPO, completed key trial enrollment, and reported a $70M net loss for 2025 - TradingView
Earnings Flash (MANE) Veradermics Posts Q4 Net Loss $21.8M - marketscreener.com
Veradermics Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Corporate and Clinical Updates - businesswire.com
Jefferies reiterates Buy on Veradermics stock, $75 target By Investing.com - Investing.com Canada
Veradermics, Incorporated(NYSE: MANE) added to S&P TMI Index - marketscreener.com
Veradermics to present hair loss treatment data at AAD meeting By Investing.com - Investing.com South Africa
Veradermics Announces Presentations on VDPHL01 and Patient Experi - The National Law Review
Veradermics to present hair loss treatment data at AAD meeting - Investing.com
Veradermics Announces Presentations on VDPHL01 and Patient Experiences With Pattern Hair Loss at 2026 American Academy of Dermatology Annual Meeting - Business Wire
Veradermics Inc (MANE) Financial Ratios - Investing.com India
Veradermics (MANE) Stock Analysis Report | Financials & Insights - Benzinga Japan
Is Veradermics (MANE) Pricing Look Attractive After Recent Pharma Sector Reappraisal? - Yahoo Finance
MANE Should I Buy - Intellectia AI
A Look At Veradermics (MANE) Valuation After Recent Share Price Momentum And DCF Upside Signals - simplywall.st
Dermatology drug maker Veradermics set for Miami investor spotlight - Stock Titan
Veradermics to Participate in Upcoming March Investor Conferences - ChartMill
Veradermics, Incorporated: Revenue and Earnings Analysts Forecasts Revisions | MANE | US9229671048 - marketscreener.com
MANE Technical Analysis & ETF Price Forecast - Intellectia AI
Veradermics, Incorporated: Dividend historical data and projections - marketscreener.com
Leerink initiates Veradermics stock with Outperform rating By Investing.com - Investing.com UK
Cantor Fitzgerald Initiates VeraDermics at Overweight - marketscreener.com
Jefferies Initiates VeraDermics at Buy With $75 Price Target - marketscreener.com
Citigroup Initiates VeraDermics at Buy With $85 Price Target - marketscreener.com
Leerink Initiates VeraDermics at Outperform With $75 Price Target - marketscreener.com
Veradermics eyes FDA first as Jefferies initiates at 'buy'; sees 75% upside on oral hair loss pill - Proactive financial news
Leerink initiates Veradermics stock with Outperform rating - Investing.com South Africa
Jefferies initiates Veradermics stock with buy rating on phase 3 prospects - Investing.com Canada
Cantor Fitzgerald initiates Veradermics stock with Overweight rating By Investing.com - Investing.com Canada
Cantor Fitzgerald initiates Veradermics stock with Overweight rating - Investing.com
Flagship-Backed Generate Biomedicines Raises $400 Million in IPO - Bloomberg.com
Flagship-Backed Generate Bio Seeks $425 Million in US IPO - Bloomberg.com
NYSE Content Update: Forgent Power Solutions, Post IPO, to Ring Opening Bell – Company Announcement - Financial Times
Assessing Veradermics (MANE) Valuation After Recent Share Price Move And Persistent Pre Revenue Losses - Yahoo Finance
Veradermics completes enrollment in second pivotal phase 3 clinical trial of Vdphl01 for male pattern hair loss - marketscreener.com
Veradermics Completes Enrollment in 2nd Phase 3 Study of VDPHL01 for Male Pattern Hair Loss - marketscreener.com
Veradermics completes enrollment in phase 3 trials for hair loss drug - Investing.com Canada
Completion of VDPHL01 Phase 3 Enrollment for Male Pattern Hair Loss - Intellectia AI
Veradermics Completes Enrollment in Second Pivotal Phase 3 Clinical Trial of VDPHL01 for Male Pattern Hair Loss - Business Wire
2.69%
0.25%
자본화:
|
볼륨(24시간):